Unisami AI News

NewLimit, founded by Coinbase CEO Brian Armstrong, raises $130M to develop age-reversing treatments

May 6, 2025 | by AI

pexels-photo-5990042

BREAKING: NewLimit’s $130M War Chest Fuels BATTLE Against Aging – Here’s How They’re Rewriting Your Biological Code

This Isn’t Sci-Fi – It’s the Future of Longevity HAPPENING NOW

NewLimit just dropped a BOMBSHELL in the anti-aging space – securing $130 million to turn back your biological clock at the cellular level. This isn’t some far-off dream – they’re reprogramming liver cells TODAY with three prototype medicines that make old cells behave like young ones again.

“We’re seeing reprogrammed liver cells process fat and alcohol like they’re 20 years younger. This is the beginning of true age reversal.”

Blake Byers, NewLimit Co-Founder

The Heavy Hitters Betting on Immortality

When Kleiner Perkins leads a round with Nat Friedman, Khosla Ventures, and Coinbase CEO Brian Armstrong (who co-founded NewLimit) throwing in their chips – you KNOW this isn’t some fly-by-night operation. These are the same visionaries who built tech empires – now they’re building longer, healthier lifespans.

  • $130M Series B – More than triple their 2023 Series A
  • Elite investor roster – Founders Fund, Garry Tan, Patrick Collison doubling down
  • AI “lab in a loop” – Screening thousands of drug candidates before they ever hit the lab

How NewLimit’s Tech Actually Works

Imagine hitting CTRL+Z on your cells. NewLimit’s epigenetic reprogramming does exactly that – taking aged liver cells and restoring their youthful function. Their secret weapon? An AI model that:

  • Simulates thousands of drug interactions
  • Identifies the most promising candidates
  • Learns from every lab result to get smarter

The Longevity Arms Race Heats Up

NewLimit isn’t alone in this fight for the fountain of youth:

  • Retro Biosciences – $180M from Sam Altman, eyeing a $1B round
  • Altos Labs – Launched with $3B from Jeff Bezos

“We’re not just adding years to life – we’re adding life to years. The first human trials will rewrite what’s possible in medicine.”

Jacob Kimmel, NewLimit Co-Founder & Stem Cell Expert

The Bottom Line

While human trials are still a few years out, NewLimit’s progress proves one thing: the aging process isn’t set in stone. With this funding injection, they’re accelerating toward a future where 80 could be the new 50 – and your liver might just outparty your grandkids.

Image Credit: cottonbro studio on Pexels

RELATED POSTS

View all

view all